Overview

Efficacy and Tolerability of MK0533 in Patients With Type 2 Diabetes (0533-005)

Status:
Terminated
Trial end date:
2007-08-01
Target enrollment:
Participant gender:
Summary
A study to evaluate the effectiveness and tolerability of MK0533 and pioglitazone in patients with type 2 diabetes mellitus.
Phase:
Phase 2
Details
Lead Sponsor:
Merck Sharp & Dohme Corp.
Treatments:
Pioglitazone